Patient-derived xenografts for individualized care in advanced sarcoma (Article first published online 4 April 2014)
AUTHORS: Justin Stebbing MA, FRCP, FRCPath, PhD, Keren Paz PhD, Gary K. Schwartz MD, Leonard H. Wexler MD, Robert Maki MD, PhD, Raphael E. Pollock MD, PhD, Ronnie Morris MD, Richard Cohen MD, Arjun Shankar MD, Glen Blackman MBBS, Victoria Harding MD, David Vasquez MD, Jonathan Krell MD, PhD, Daniel Ciznadija PhD, Amanda Katz MD and David Sidransky MD
BACKGROUND: Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of-care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method (“TumorGrafts”).
CONCLUSIONS: The current data support the use of the personalized TumorGraft model as an investigational platform for therapeutic decision-making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician’s choice is warranted. Cancer 2014. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Download the paper in PDF format here.